NASDAQ:OPHT - Ophthotech Corporation
$1.43
 $0.00
0.00%
2:15PM EDT
2019-02-15
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  OPHT     avg for
industry  
  avg for
sector  
42 stocks weight:  22. 01   0. 00   0. 00  
42 stocks rank:  3. 59 K 1. 86 K 1. 09 K
# analyst opinions:  2. 00   14. 92   14. 43  

quick ratio:  12. 84   5. 37   1. 81  
current ratio:  13. 04   5. 69   2. 19  

target price low:  1. 10   88. 97   117. 82  
target price avg:  1. 27   115. 19   141. 96  
target price high:  2. 55   143. 40   163. 16  
1-yr high:  3. 23   124. 30   142. 77  
last close:  1. 43   101. 85   127. 84  
50-day avg:  1. 34   98. 27   122. 46  
200-day avg:  2. 20   99. 72   122. 70  
1-yr low:  1. 07   78. 19   100. 16  
volume:  315. 60 K 2. 38 M 4. 64 M
50-day avg volume:  279. 76 K 3. 31 M 4. 94 M
200-day avg volume:  341. 04 K 3. 23 M 4. 28 M

1-day return:  2. 14 % 0. 22 % 0. 48 %
this week return:  8. 33 % 1. 77 % 2. 01 %
12-wk return:  -25. 13 % 6. 56 % 3. 33 %
52-wk return:  -52. 17 % -2. 23 % 14. 35 %

enterprise value (EV):  44. 26 M 55. 17 B 104. 51 B
market cap:  59. 01 M 49. 01 B 96. 46 B
EBITDA:  -56. 27 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 79   -91. 79   2. 29  
total revenue:  0. 00   11. 28 B 40. 22 B
total debt:  125. 00 M 13. 73 B 16. 57 B
debt/equity:  2. 30 K 258. 01   110. 73  
net income (common):  -50. 57 M 2. 37 B 3. 58 B

shares outstanding:  41. 27 M 607. 99 M 1. 22 B
shares:  30. 89 M 605. 53 M 1. 15 B
shares short:  371. 99 K 11. 62 M 12. 55 M
shares short prior month:  381. 88 K 11. 95 M 13. 44 M
short ratio:  0. 98   4. 82   3. 10  
short % of float:  1. 03 % 6. 19 % 2. 82 %
total cash/share:  3. 28   12. 02   11. 46  
total cash:  135. 21 M 7. 41 B 7. 37 B
free cash flow:  -26. 71 M 95. 99 M 2. 04 B
operating cash flow:  -45. 07 M 164. 74 M 3. 04 B

book value:  0. 15   14. 43   28. 26  
price/book:  9. 53   -1. 57   -2. 97  
gross profits:  151. 19 M 8. 28 B 18. 09 B
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  10. 36 % --- ---
1-yr mean volatility:  -0. 21 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 40   3. 03   4. 09  
forward EPS:  -1. 48   4. 33   6. 99  
P/E:  -1. 02   6. 11   26. 91  
forward P/E:  -0. 89   8. 38   10. 48  
PE/G:  0. 02   0. 37   5. 61  
growth:  -42. 28 % 683. 72 % 104. 79 %
earnings high:  -0. 37   1. 27   1. 66  
earnings avg:  -0. 41   1. 01   1. 53  
earnings low:  -0. 44   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -22. 07 % -3. 27 % 3. 81 %
return on equity:  -205. 14 % 107. 48 % 27. 82 %
revenue/share:  0. 00   14. 68   59. 83  

beta (1yr vs S&P500):  0. 56   1. 21   0. 93  
sharpe (1yr):  -1. 30   0. 06   0. 98  

held % insiders:  0. 58 % 6. 46 % 3. 21 %
held % institutions:  66. 59 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : OPHT
.        + 0 =             0 :: INITIAL WEIGHT
.   + 324.54 =        324.54 :: inverse volume-to-price addition
.   + 99.111 =       423.651 :: spline projection addition
.  - 124.195 =       299.456 :: poor performance penalty
.    x 0.702 =       210.272 :: one-year gains+dividend factor
.    x 7.677 =      1614.183 :: 13 weeks' performance factor
.    x 1.492 =       2409.15 :: industry recommendation factor
.    x 0.998 =      2403.834 :: return on assets factor
.    x 0.979 =      2354.522 :: return on equity factor
.    x 2.289 =      5390.505 :: current ratio factor
.    x 1.041 =      5613.531 :: quick ratio factor
.    x 1.421 =      7979.133 :: short ratio factor
.    x 2.198 =     17536.391 :: price-to-book factor
.    x 2.123 =     37235.059 :: debt-to-equity factor
.    x 1.028 =     38275.804 :: 5-day avg > 50-day avg
.    x 2.171 =     83093.209 :: P/E weight
.    x 2.209 =    183549.501 :: PE/G factor
.    x 1.675 =    307466.345 :: beta factor
.    x 0.587 =    180547.178 :: sharpe factor
.    x 0.952 =    171873.972 :: target low factor
.    x 0.941 =    161787.593 :: target mean factor
.    x 1.088 =    176105.719 :: target high factor
.    x 1.066 =     187660.51 :: industry 12-weeks return
.    x 0.999 =    187447.726 :: overall "drift" factor
.    x 0.896 =      168033.5 :: largest single-day jump factor
.    x 0.063 =     10668.794 :: low price factor
.      x 1.0 =      10669.51 :: factor hist industry gain for week 06
.   cubeRoot =        22.015 :: reduced for readability
.                     22.015 :: FINAL WEIGHT for NASDAQ:OPHT


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org